Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

Osteonecrosis of the jaw (ONJ) was defined as exposed, necrotic bone in the maxillofacial
region for at least 8 weeks in patients receiving an antiresorptive medication for primary or …

The significant clinical feature of bisphosphonate-related osteonecrosis of the jaw (BRONJ)
is the exposure of the necrotic jaw. Other clinical manifestations include jaw pain, swelling …

Bisphosphonates are often used to treat osteoporosis, malignant bone metastases, and
hypercalcemia. However, it can cause serious adverse reactions, bisphosphonate-related …

The mechanism and effective treatment of bisphosphonate-related osteonecrosis of the jaw
(BRONJ) are still uncertain. Our previous study revealed that zoledronate (ZOL) …

Medication related osteonecrosis of the jaws (MRONJ) and osteoradionecrosis of the jaws
(ORNJ) are two different diseases of quite similar appearance. MRONJ is mainly due to …

Purpose Bisphosphonates related osteonecrosis of jaw (BRONJ) is a severe complication of
systemic BPs administration, the mechanism of which is still unclarified. Recently, platelet …

Background Long-term use of anti-resorptive or anti-angiogenic drugs in cancer patients
with odontogenic infections may lead to medication-related osteonecrosis of the jaw …

The development of novel 3D tissue culture systems has enabled the in vitro study of in vivo
processes, thereby overcoming many of the limitations of previous 2D tissue culture …

The anti-angiogenic effects of bisphosphonates have been hypothesized as one of the
major etiologic factors in the development of medication-related osteonecrosis of the jaw …